Saturday, October 3, 2026
21.3 C
Bengaluru

Indian Pharma Market (IPM) Highlights – January 2025

Overall IPM Performance:

  • Monthly Growth: IPM monthly growth reached 8.4% in January 2025, following a pattern of significant monthly fluctuations throughout the year.
  • MAT Growth: The Moving Annual Total (MAT) growth for January 2025 slightly increased to 7.7%, up from 7.6% in December 2024.

Acute vs. Chronic Segment Analysis:

  • Chronic Segment Dominance: The chronic segment continued to outperform the acute segment, with a MAT growth of 9.9% compared to 6.3% for the acute segment in January 2025.
  • Growth Rate Declines: While the chronic segment's growth rate only slightly decreased (by 1.1%), the acute segment experienced a more substantial decline (3.2%) compared to January 2024.

Monthly Growth Trends:

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical...

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

India’s anaemia challenge is not simply about access to...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

Topics

spot_img

Related Articles

spot_imgspot_img